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Brain atrophy measured by magnetic resonance structural imaging has been proposed as a surrogate marker for the early
diagnosis of Alzheimer’s disease. Studies on large samples are still required to determine its practical interest at the individual
level, especially with regards to the capacity of anatomical magnetic resonance imaging to disentangle the confounding role of
the cognitive reserve in the early diagnosis of Alzheimer’s disease. One hundred and thirty healthy controls, 122 subjects
with mild cognitive impairment of the amnestic type and 130 Alzheimer’s disease patients were included from the ADNI
database and followed up for 24 months. After 24 months, 72 amnestic mild cognitive impairment had converted to
Alzheimer’s disease (referred to as progressive mild cognitive impairment, as opposed to stable mild cognitive impairment).
For each subject, cortical thickness was measured on the baseline magnetic resonance imaging volume. The resulting cortical
thickness map was parcellated into 22 regions and a normalized thickness index was computed using the subset of regions
(right medial temporal, left lateral temporal, right posterior cingulate) that optimally distinguished stable mild cognitive
impairment from progressive mild cognitive impairment. We tested the ability of baseline normalized thickness index to
predict evolution from amnestic mild cognitive impairment to Alzheimer’s disease and compared it to the predictive values
of the main cognitive scores at baseline. In addition, we studied the relationship between the normalized thickness index,
the education level and the timeline of conversion to Alzheimer’s disease. Normalized thickness index at baseline differed
signiﬁcantly among all the four diagnosis groups (P_0.001) and correctly distinguished Alzheimer’s disease patients from
healthy controls with an 85% cross-validated accuracy. Normalized thickness index also correctly predicted evolution to
Alzheimer’s disease for 76% of amnestic mild cognitive impairment subjects after cross-validation, thus showing an advantage
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1 year after baseline, showed a signiﬁcantly higher education level than those who converted earlier than 1 year after baseline.
Using a normalized thickness index-based criterion may help with early diagnosis of Alzheimer’s disease at the individual level,
especially for highly educated subjects, up to 24 months before clinical criteria for Alzheimer’s disease diagnosis are met.
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MMSE=Mini Mental State Examination; MRI=Magnetic Resonance Imaging; NTI=Normalized Thickness Index;
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Introduction
Clinical evaluation and neuropsychometry have shown their limits
(Mueller et al., 2005; Venneri, 2007) for predicting evolution from
the prodromal stage of Alzheimer’s disease (i.e. mild cognitive
impairment, MCI) (Petersen et al., 1999; Petersen, 2003) to the
dementia stage. One of the major limits on prediction comes from
the cognitive reserve, which acts as a confounding factor and may
hide the early signs of the disease, especially for subjects with
a high education level, who would be more successful at coping
with greater brain damage (Mortimer et al., 2005; Stern, 2006;
Roe et al., 2007). Alternatively, various types of neuroimaging
have shown promising capacities for measuring the early onset
of Alzheimer’s disease, including MRI (Mungas et al., 2002; Jack
et al., 2003) and cerebral glucose metabolism or beta amyloid
imaging with positron emission tomography (Alexander et al.,
2002; Engler et al., 2006). Moreover, some recent studies have
investigated the interaction between the cognitive reserve factor
and neuroimaging modes (Sole-Padulles et al., 2007; Hanyu et al.,
2008; Kemppainen et al., 2008), and have shown that neuro-
imaging measurements may reﬂect the underlying pathology
better than neuropsychometry since they are less affected by
cognitive reserve, which, in turn, is linked to education level
(Stern, 2006).
While brain metabolism or amyloid deposition may show higher
sensitivity or speciﬁcity for the early detection of the disease (Small
et al., 2006), structural MRI offers important advantages, such as
greater availability, faster data acquisition, lower cost and the
possibility of automatically deriving quantitative indices of regional
atrophy (Mueller et al., 2006). Accordingly, the validation of struc-
tural MRI as a marker of Alzheimer’s disease progression is the
core project of the Alzheimer’s Disease Neuroimaging Initiative
(ADNI).
In this perspective, we have developed a fast (20min per
volume), robust and fully automated method for cortical thickness
measurement. As an alternative to volumetric methods, cortical
thickness measurement has given promising results while
being less operator-dependent than hippocampal volume mea-
surements and more suitable for quantiﬁcation and localization
(Lerch et al., 2005) than voxel-based morphometry (Ashburner
and Friston 2000). Lerch et al. (2005) have also established a
link between histopathologically conﬁrmed pathological changes
and cortical atrophy assessed through cortical thickness
measurement. We tested the effectiveness of our method on
cross-sectional data obtained from the ADNI database. We then
assessed the power of cognitive testing and of cortical thickness to
predict evolution from amnestic MCI to Alzheimer’s disease at the
individual level over a period of 24 months, with a particular
emphasis on the possible impact of the cognitive reserve, using
cortical thickness as a proxy for brain damage.
Methods
Study set-up and design
Data used in the preparation of this article were obtained from the
ADNI database (www.loni.ucla.edu/ADNI). The ADNI was launched
in 2003 by the National Institute on Aging (NIA), the National
Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food
and Drug Administration (FDA), private pharmaceutical companies
and non-proﬁt organizations as a $60 million, 5-year public–private
partnership. The primary goal of ADNI has been to test whether
serial MRI, PET, other biological markers and clinical and neuro-
psychological assessment can be combined to measure the progression
of mild cognitive impairment (MCI) and early Alzheimer’s disease.
Determination of sensitive and speciﬁc markers of very early
Alzheimer’s disease progression is intended to aid researchers and
clinicians in the development of new treatments and monitor their
effectiveness, as well as lessen the time and cost of clinical trials (for
more details, see Supplementary material).
Inclusion and diagnostic criteria
The general inclusion criteria were those of the ADNI (http://clinical
trials.gov/show/NCT00106899). According to ADNI clinical proce-
dures, diagnosis of Alzheimer’s disease was made if the subject had
a Mini Mental State Examination (MMSE) (Folstein et al., 1975) score
between 20 and 26, a Clinical Dementia Rating scale (Morris, 1993)
score of 0.5 or 1, and met NINCDS/ADRDA (McKhann et al., 1984)
criteria for probable Alzheimer’s disease.
Individuals were classiﬁed as single-domain amnestic MCI if they
satisﬁed the following criteria: (i) score on the MMSE between
24 and 30; (ii) Clinical Dementia Rating scale=0.5; (iii) reported
memory complaint; (iv) objective memory loss measured by educa-
tion-adjusted scores on Wechsler Memory Scale Logical Memory II
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other cognitive domains; (vi) preserved activities of daily life; and
(vii) absence of dementia.
Healthy controls had an MMSE score between 24 and 30 and
a Clinical Dementia Rating scale score of 0. Whatever the inclusion
group, subjects had a Geriatric Depression Scale score of less than 6.
Participants
Four hundred and forty-four subjects from the ADNI database were
included in our study (Fig. 1). These subjects were selected randomly,
respecting roughly a 1:1:1 ratio (healthy controls: amnestic MCI:
Alzheimer’s disease patient). Fifty-six subjects (12.6%) were
subsequently excluded because of unsuccessful cortical thickness
measurement due to poor image quality.
Every subject received a baseline clinical evaluation and was
re-evaluated every six months after inclusion, over a total period of
24 months. After 24 months, 72 amnestic MCI had converted to
Alzheimer’s disease (hereafter referred to as progressive MCI, as
opposed to stable MCI) and six healthy controls had converted
amnestic MCI (and were thus excluded from the study). The resulting
cross-sectional population was ﬁnally composed of 130 healthy
controls, 50 stable MCI, 72 progressive MCI and 130 Alzheimer’s
disease patients, whose demographic data are presented in Table 1.
For the cognitive reserve analysis, all the subjects were dichotomized
in two groups: the Lower Education Group consisted of the subjects
with an education level lower than the mean education level of the
amnestic MCI sample, i.e. subjects with 415 years of education, and
the Higher Education Group consisted of the subjects with an educa-
tion level equal to or416 years of education. To assess the predictive
value of our methodology on a test set, a subset consisting of
30 healthy controls and 30 Alzheimer’s disease patients, who did
not differ in terms of age, education, gender or MMSE score from
the remaining 100 healthy controls and 100 Alzheimer’s disease
patients, was randomly selected.
Neuropsychological scores
The delayed recall performance in the Auditory Verbal Learning Test
(Rey, 1964) and in the Alzheimer’s disease Assessment Scale score
(ADAS-Cog) 10-Word list (Rosen et al., 1984) were selected from
the cognitive measures included in the ADNI database because
delayed recall has been shown to be a strong predictor of
Alzheimer’s disease (Estevez-Gonzalez et al., 2003; Rountree et al.,
2007). Complementary to memory performance, executive functions
were evaluated by Trail Making Test B (time to complete) and a
measure of global functioning was provided by the MMSE score.
Information on conversion from healthy controls to amnestic MCI
and from amnestic MCI to Alzheimer’s disease was used as given in
the ADNI database (after review by the Central Review Committee,
according to the ADNI procedures).
MRI volumes
MRI volumes at baseline were downloaded from the ADNI database.
All the volumes were acquired on a 1.5 Tesla scanner. However, as
ADNI is a multicentre project, other acquisition parameters were
speciﬁc to the centres concerned.
Method of cortical thickness
measurement
All the procedures described below (segmentation, cortical thickness
measurement, cortical thickness map parcellation) were implemented
in-house. A validation procedure was carried out using publicly avail-
able simulated population data (Lerch and Evans, 2005). More details
on this validation are provided in the supplementary data.
Volumes were resampled to a 111mm resolution, then
segmented using an in-house reimplemented segmentation algo-
rithm, which followed the procedure described by Ashburner and
Friston (1997). Using the grey matter, white matter and cerebrospinal
Figure 1 Inclusion diagram.
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the whole cortical ribbon in the native space of the subject’s brain,
using a Laplace’s-equation-based algorithm as described by Jones
et al. (2000). To take into account partial volume effects at the
white matter/grey matter and cerebrospinal ﬂuid/grey matter inter-
faces, a boundary cortical thickness was derived by using a fuzzy
distance method (Bloch, 2004), which led to a sub-millimetric mea-
surement of cortical thickness.
By computing cortical thickness for the entire cortical ribbon, a 3D
cortical thickness map was obtained, which was then registered in
the standardized MNI space (Evans and Collins, 1993) using
nine-parameter rigid registration (ITK Software
, Ixico, London)
(Studholme et al., 1999).
Cortical thickness map parcellation
The registered cortical thickness map was parcellated into 96 areas
(48 Brodmann areas2 hemispheres) using the Brodmann area 3D
map given by the MRIcro package (http://www.sph.sc.edu/comd/
rorden/mricro.html). To reinforce the robustness of the measures,
these areas were then grouped into 22 zones (11 zones2 hemi-
spheres) deﬁned by three neurologists (J.P., J-F.D., M.P.) following
pathophysiological criteria (see Supplementary data, Table 1).
A mean cortical thickness was computed for each zone of each
subject.
Normalized thickness index
We developed a Normalized Thickness Index (NTI) that measured the
severity of brain atrophy, for a single subject, on a continuum between
healthy state and Alzheimer’s disease. The NTI was designed to take
age into account since cortical thickness decreases with age (Salat
et al., 2004), and to provide a single, normalized measure instead of
a set of raw measurements obtained from different zones.
The NTI computation is based on a supervised learning approach.
The ﬁrst paragraph below describes the generic process to compute a
parametrical NTI, which depends on the subset of zones used for the
computation among the 22 available. The optimal subset of zones that
best discriminated stable MCI subjects from progressive MCI subjects
was then chosen according to a procedure that we describe in the sec-
ond paragraph.
First, to compute the NTI corresponding to any subset of n zones
among the 22 zones of a subject S, 50 healthy controls and
50 Alzheimer’s disease patients were randomly selected from their
respective groups (involving the 100 healthy controls and 100
Alzheimer’s disease patients who constituted the learning sets).
These subsets were used as a training sample. If the considered subject
S (for whom the NTI was to be computed) belonged to the healthy
controls or the Alzheimer’s disease groups, he/she was discarded so as
not to be included in the training sample. A normalized linear
discriminant function was computed, taking age and the mean cortical
thickness values of the n zones into account. The function was
normalized by centring the learning set of healthy controls on 1 and
that of Alzheimer’s disease patients on 1. This function was then
applied to the subject S and gave a temporary NTI. To prevent
the NTI from being dependent on the learning sets, the whole
process was repeated a hundred times (always by choosing the
learning sets at random). The ﬁnal NTI for the subject S was
the average of the hundred values obtained.
We then used an automatic procedure to determine the optimal
subset of zones among the 22, which was led by our main goal of
best discriminating the stable MCI from the progressive MCI. For each
amnestic MCI subject, we computed an NTI for every possible subset
of zones regardless of their number and spatial normalization. For
each possible NTI, a Receiver Operating Curve (ROC) was computed
and the Area under the ROC was stored. We ﬁnally selected the
subset whose NTI yielded the best Area under the ROC between
stable MCI and progressive MCI. As a result of the procedure, the
optimal combination of zones included the right posterior cingulate,
the right medial temporal zone and the left lateral temporal zone.
Additionally, a cross-validation process was used to test whether this
optimal subset of zones depended on the amnestic MCI sample (for
more details, see Supplementary material).
In what follows, the term ‘NTI’ will refer to the NTI computed with
this optimal subset of zones.
Statistical analysis
Global analysis on cortical thickness
For each of the 22 zones, mean cortical thicknesses were compared
between diagnosis groups by a multiple analysis of covariance with
three intergroup factors (Gender, Diagnosis and ApoE) and two
covariates (Age and Education), to correct for their signiﬁcant effects
Table 1 Demographic and clinical characteristics according to diagnosis group
Variable Diagnosis group P-value
Healthy controls
(n=130)
Stable MCI
(n=50)
Progressive MCI
(n=72)
Alzheimer’s disease
patients (n=130)
Age (years) 75.75.2 75.66.9 75.37.0 75.07.2 0.90
ApoE (%)
a 27.0 42.0 63.9 70.6 50.001
Education level (years) 16.32.4 15.92.7 15.72.8 14.82.9 0.001
Sex 58M/42F 34M/16F 47M/25F 58M/42F 0.54
Cognitive scores
MMSE 29.20.9 27.41.8 26.51.8 23.12.1 50.001
ADAS-Cog, 10-word list delayed recall 7.21.7 4.12.5 2.61.9 1.21.4 50.001
AVLT delayed recall 7.63.7 3.53.8 1.31.9 0.51.3 50.001
TMTB time to complete (s) 80.729 101.252.2 152.179.4 194.396.5 50.001
Plus–minus values are meansSD. P-values correspond to the differences between the four diagnosis groups.
a The given percentage indicates the proportion of individuals carrying at least one allele E4.
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‘Healthy Controls’, ‘progressive MCI’, ‘stable MCI’ and ‘Alzheimer’s
disease’, and the ApoE factor had two levels (no E4 allele, and at
least one E4 allele).
The NTI was globally validated by testing its power to discriminate
between healthy controls and Alzheimer’s disease patients. A ﬁrst step
computed the optimal threshold to separate the 100 healthy controls
from the 100 Alzheimer’s disease patients of the learning set, using
10-fold cross validation. This optimal threshold was then applied to the
test set (30 healthy controls and 30 Alzheimer’s disease patients).
Cognitive reserve analysis
The NTI was compared between the two education groups by a
multiple analysis of variance with two inter-group factors (Diagnosis
and Education Level Group). The same analysis scheme was used to
compare the MMSE scores between the two groups.
Predictive value analysis
We tested the power of the NTI and of neuropsychological scores to
discriminate progressive MCI from stable MCI using ROC. Area under
the ROC values (used to appraise the discriminant power of each
parameter) were compared between each other using a non-
parametric method for correlated samples (DeLong et al., 1988).
The NTI and the neuropsychological scores were tested independently
by submitting each of them to a one-level decision tree. Discriminant
power was measured through the misclassiﬁcation cost, computed by
a 10-fold cross validation as provided by Matlab Statistics Toolbox.
Our index was combined with the neuropsychological scores using
a linear classiﬁcation tree. The discriminant power was measured as
explained above, and the pruning level of the tree was chosen so as to
obtain the lowest cross validated misclassiﬁcation cost.
Finally, we chose the optimal threshold of the NTI given by the one-
level decision tree analysis described above as the best criterion for
detecting Alzheimer’s disease at its prodromal stage. We hypothesized
that there might be a time difference between the observation of an
NTI below the threshold at baseline and the effective conversion to
Alzheimer’s disease. To test this hypothesis, we applied the optimal
threshold to the whole set of amnestic MCI subjects, thus separating
them into two groups: amnestic MCI subjects having an NTI below the
threshold (referred to as anatomically demented) and amnestic MCI
subjects having an NTI above the threshold (referred to as anatomi-
cally healthy). At each clinical re-evaluation, we reported the clinical
outcome (stable MCI versus progressive MCI) of anatomically healthy
and anatomically demented subjects by means of a 22
contingency table (NTI threshold versus clinical outcome).
MANCOVA was performed using Statistica (version 6.1); decision
trees and ROCs were computed using Matlab (version 7.5).
Results
Global analysis
Cortical thickness differed signiﬁcantly between the diagnosis
groups (P50.001) (Table 2, Fig. 2).
Moreover, a signiﬁcant-differences Newman–Keuls post hoc
analysis showed that all the diagnosis groups differed from each
other in terms of cortical thickness. Cortical thickness signiﬁcantly
decreased with age (P50.001), while people with a high level of
education showed a signiﬁcantly thinner cortex (P=0.001).
Subjects carrying at least one ApoE4 allele had a signiﬁcantly
thinner cortex than those carrying none (P=0.04).
Results of the 10-fold cross validation for the healthy controls/
Alzheimer’s disease patients classiﬁcation showed that the NTI
correctly classiﬁed 85% of the subjects. The optimal threshold
was found at NTI=0. This threshold was used on the test
sample of 30 healthy controls and 30 Alzheimer’s disease patients,
a sample which was completely independent of that used to
compute NTI threshold; this procedure correctly classiﬁed these
subjects again at the rate of 85%.
Cognitive reserve analysis
Education level differed signiﬁcantly (P510
-4) between the Higher
Education group (mean 17.4 years0.2) and the Lower Education
group (mean 12.6 years  0.3). There was no signiﬁcant differ-
ence (P=0.15) in terms of MMSE (Fig. 3B) between Higher
Education and Lower Education subjects, but a signiﬁcant main
effect of Diagnosis (P510
4). A Newman–Keuls post hoc test
led to four homogeneous groups: {MMSEHC}4{MMSEsMCI}4
{MMSEpMCI}4{MMSEAlzheimer’s disease}. No interaction was found
between the Diagnosis and Education Group (P=0.70), suggesting
that, for all the four diagnosis groups, Higher Education and Lower
Education subjects had the same cognitive level.
As expected, there was a signiﬁcant effect of diagnosis
(P510
4) on the NTI. A Newman–Keuls post hoc test
led to three homogeneous groups: {NTIHC}4{NTIsMCI}4
{NTIpMCINTIAlzheimer’s disease} (Fig. 3A), which indicates that
progressive MCI subjects and Alzheimer’s disease patients cannot
be distinguished in terms of NTI. There also was an Education
Level Group effect (P=0.002), with subjects of higher education
level presenting a lower NTI. No interaction between diagnosis
and education Level was found (P=0.848).
Discrimination stable MCI/progressive
MCI
NTI power to discriminate stable MCI from progressive MCI was
compared with the discriminant power of cognitive scores, age
Table 2 Magnitude of effects of various factors on mean
cortical thickness values
Effect P-value Level Value
Diagnosis 50.001 Healthy controls 2.460.03
Stable MCI 2.330.03
Progressive MCI 2.260.04
Alzheimer’s disease 2.170.04
Gender 0.68 Male 2.30.03
Female 2.310.03
Apoe 0.04 Carrier 2.310.03
Non-carrier 2.370.03
Age 50.001 NA 0.400.04
Education 0.001 NA 0.120.04
For main effects (Diagnosis, Sex, Apoe), plus–minus values are means of cortical
thickness (in mm)SD. For covariates (Age, Education), plus–minus values
are the estimators of the b coefﬁcientSD, i.e. regression slopes calculated
on centred scaled values.
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cation (Area under the ROC = 0.530.04) classiﬁed subjects
nearly at random and had a signiﬁcantly lower Area under the
ROC than the NTI and the cognitive scores. NTI had a signiﬁcantly
higher Area under the ROC (0.760.04) with respect to Auditory
Verbal Learning Test (0.670.04), ADAS-cog 10-word list
delayed recall (0.670.04), and MMSE (0.640.04), but there
was no signiﬁcant difference with the Trail Making Test B
(0.720.04).
Misclassiﬁcation costs computed for the one-level decision trees
were of the same order of magnitude as the Area under the ROC
(see Supplementary data, Table 2). As for the healthy controls/
Alzheimer’s disease patients discrimination, the NTI optimal
threshold for the discrimination between stable MCI and progres-
sive MCI was again found at NTI=0.
Combining the cognitive scores, age and education gave a
correct classiﬁcation for 61% of the subjects. None of the possible
combinations of NTI and cognitive scores improved the cross-
validated predictive value of the one-level decision tree with the
NTI alone.
NTI criterion: prediction of the clinical
outcome
The NTI criterion detected 77 anatomically demented out of the
122 amnestic MCI. Among these 77 anatomically demented,
16 were progressive MCI at 6 months (21%), 36 were progressive
MCI at 12 months (47%), 51 were progressive MCI at 18 months
(66%) and 58 were progressive MCI at 24 months (75%)
(Table 3).
The NTI criterion detected 45 anatomically healthy. Among
these 45 anatomically healthy, 42 were stable MCI at 6 months
(93%), 34 were stable MCI at 12 months (76%), 33 were stable
MCI at 18 months (73%) and 31 were stable MCI at 24 months
(69%). Thus, the sensitivity of the NTI rose from 21% at
6 months to 75% at 24 months, and its speciﬁcity evolved from
93% to 69%. The resulting accuracy of this criterion rises, there-
fore, from 48% at 6 months to 73% at 24 months.
From a practical point of view, NTI detected 80.6% (58/72) of
the patients who were to be clinically diagnosed as patients with
Alzheimer’s disease 24 months later. The cognitive reserve may
have an impact on the timeline of conversion to Alzheimer’s
disease. Therefore, even after anatomical signs of brain damage
are observed, the time to clinical conversion may be modulated
according to the education level of the patient. To test this
hypothesis, we compared the education level among four
groups. The ﬁrst group, for sake of comparison, included stable
MCI subjects who had a positive NTI at baseline. The second
group included progressive MCI subjects who converted to
Alzheimer’s disease at 6 or 12 months after baseline, the third
group included the progressive MCI subjects who converted to
Alzheimer’s disease at 18 or 24 months, and the fourth group
included the stable MCI with an NTI negative score (an anatomical
pattern similar to that of Alzheimer’s disease patients) (Fig. 4).
There was a signiﬁcant difference of education level among
these four groups (P=0.04), with the fourth group having
the highest education level. Planned comparison between the
Figure 2 Baseline mean cortical thickness values according to the diagnosis groups. Normalized values obtained after controlling for
age, education, sex and ApoE. Vertical bars represent the 95% conﬁdence interval for the mean estimators. For each of the 22 areas,
mean cortical thickness was highest in the healthy controls group and lowest in the Alzheimer’s disease group.
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group (converters at 18 or 24 months) gave a nearly signiﬁcant
difference of education level (P=0.06).
The effect of educational level on the prediction of conversion
according to the NTI was achieved by comparing the education
level (in years) between amnestic MCI subjects that were properly
classiﬁed by the NTI and amnestic MCI that were misclassiﬁed by
the NTI [i.e. anatomically healthy subjects that had converted to
Alzheimer’s disease during the study period (false negative) or
anatomically demented subjects that had still not converted at
24 months after baseline (false positive)]. No signiﬁcant differ-
ence was found (P=0.97), showing that the global reliability
of the method was not affected by education level. Additionally,
we investigated whether there was an effect of education on
misclassiﬁcation with respect to the diagnosis group (stable MCI
or progressive MCI). Amnestic MCI subjects were classiﬁed into
four groups according to their education level (‘lower than or
equal to 15 years’ or ‘higher than 15 years’) and their diagnosis
groups (‘sMCI’ or ‘pMCI’). A contingency table was built (Table 4)
and a Fisher exact test was done on this table, which revealed
Figure 3 Comparison of NTI (A) and MMSE (B) between Education Groups, according to their Diagnosis Groups HC, Healthy Control;
sMCI, stable MCI; pMCI, progressive MCI; NS, Not Signiﬁcant. (A) A signiﬁcant main effect of Education on the NTI (*P=0.002).
The NTI also differs signiﬁcantly across diagnosis groups (P510
4), with no interaction between Education and Diagnosis (P=0.85).
(B) No main effect of education on the MMSE (NS, P=0.15). The MMSE differs signiﬁcantly across diagnosis groups (P510
4), with
no interaction between Education and Diagnosis (P=0.70). For more details, see post hoc tests in the results section.
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classiﬁed subjects were stable MCI subjects with a high level of
education.
Discussion
To evaluate the capacity of MRI to improve Alzheimer’s disease
early diagnosis at the individual level, we designed a fast, auto-
mated method for assessing whether the MRI measurement of
cortical thickness could predict progression to Alzheimer’s disease
from its prodromal stage at individual level. Applying our cortical
thickness based Normalized Index (NTI) to a large sample of
patients from the ADNI database, we found evidence that struc-
tural MRI can be used to detect subtle structural changes that help
predict the subject’s outcome up to 24 months before clinical
diagnosis. We also investigated the cognitive reserve hypothesis
on our population and showed that subjects with a higher educa-
tion level had a signiﬁcantly thinner cortex than less educated
subjects with the same level of cognitive performance. For these
subjects, structural imaging may thus appear more sensitive to
the incipient disease than cognitive testing.
The preliminary validation process we used showed that our
methodology was reliable. The cortical values measured in this
study are consistent with reported measurements of cortical thick-
ness, in particular regarding the signiﬁcant effects of age and ApoE
genotype, or the non-signiﬁcant effect of gender, as well as the
differences in cortical thickness regional patterns observed
between healthy controls, amnestic MCI and Alzheimer’s disease
patients (Salat et al. 2004; Lerch and Pruessner, 2005; Singh et al.,
2006; Shaw et al., 2007; Teipel et al., 2007). Interestingly, our
results in terms of regional atrophy between healthy controls,
amnestic MCI and Alzheimer’s disease patients are very similar
to those of other studies based on the ADNI data (Fan et al.,
2008; Hua et al., 2008). The NTI may also be considered as an
accurate and robust index of Alzheimer’s disease, since it yielded a
high cross-validated accuracy (85%) for distinguishing Alzheimer’s
disease patients from healthy controls on a set of subjects that was
distinct from the one used for the NTI computation.
For the construction of the NTI, we retained the right posterior
cingulate, the right medial temporal zone and the left lateral
temporal zone as the optimal combination of zones. However,
this choice of zones is not critical regarding the predictive accu-
racy, since numerous combinations can lead to the same accuracy
as illustrated in the supplementary Table. This can be explained by
the fact that widely spread cortical atrophy was observed in the
progressive MCI population, which may indicate that these
subjects were already at an advanced stage of the disease from
an anatomical point of view, despite the fact that they had still not
been clinically diagnosed as Alzheimer’s disease patients. Had
these patients been at an earlier stage of the disease, a more
focal atrophy might have been observed, resulting in a smaller
Figure 4 Effect of the education level on the timeline of
conversion to Alzheimer’s disease. Progressive MCI subjects
who converted at 6 or 12 months had a lower education level
than progressive MCI subjects who converted at 18 or 24
months. In addition, stable MCI subjects who were detected at
baseline as having an NTI negative score (thus showing a
pathological anatomical pattern) had an education level slightly
higher than that of progressive MCI subjects who converted at
more than a year after baseline, suggesting that they may soon
convert to Alzheimer’s disease. For comparison, stable MCI
subjects with a positive NTI were included in the model, and
showed a ‘moderate’ education level when compared to stable
MCI subjects with an NTI negative score.
Table 3 Time shift between detection of atrophy and
clinical conversion
pMCI sMCI
At 6 months
aD 16 61
aH 3 42
Total 19 103
At 12 months
aD 36 41
aH 11 34
Total 47 75
At 18 months
aD 51 26
aH 12 33
Total 63 59
At 24 months
aD 58 19
aH 14 31
Total 72 50
At baseline, 77 subjects were classiﬁed as aD and 45 as aH. Therefore, the
sums of the ﬁgures across the lines remain constant at 6, 12, 18 and 24
months. In contrast, the total of sMCI decreased over time as the total of
pMCI increased, reﬂecting disease’s progression throughout the study period.
The four panels show the cumulative occurrences of conversion for the aD
and aH subjects at 6, 12, 18 and 24 months.
aH=anatomically Healthy (NTI50), aD=anatomically Demented (NTI50).
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optimal combinations. Further studies on other amnestic MCI
populations (or possibly on a preclinical population) are still
required to analyse the respective predictive accuracies of these
combinations at earlier stages of the disease.
We found that the NTI was able to accurately predict evolution
from amnestic MCI to Alzheimer’s disease up to 24 months before
clinical criteria of Alzheimer’s disease are met, with a cross-
validated predictive value of 76%. Results from the literature
give varied assessments of the ability of structural imaging and
of cognitive scores (alone or combined) to predict conversion to
Alzheimer’s disease. Korf et al. (2004) showed that atrophy in the
medial temporal lobe could predict conversion to Alzheimer’s
disease with a global accuracy of 69%. Sarazin et al. (2007)
showed that cognitive scores could predict future conversion to
Alzheimer’s disease with high accuracy (94%), but the age differ-
ence alone between their two groups classiﬁed 72% of the indi-
viduals. Devanand et al. (2007) found that a combination of
cognitive scores and hippocampal and entorhinal cortex volumes
could predict conversion to Alzheimer’s disease with an accuracy
of 87.7%; however, age alone correctly classiﬁed 71.9% of the
subjects, and their follow-up period (5 years in average) was much
longer than ours. Visser et al. (2002) showed that a combination
of cognitive scores, hippocampal and parahippocampal volumes
and visually assessed atrophy of the medial temporal lobe could
predict conversion to Alzheimer’s disease for 81% of the subjects,
but age on its own classiﬁed 78% of the subjects. In our study,
age was not a relevant predictor, since we showed that it classiﬁed
subjects nearly randomly (Area under the ROC=0.52). More
importantly, our present study has the crucial advantage of
using a cross-validation procedure that guarantees higher validity
of the estimation of predictive values than those reported by other
studies which tested predictive values within a single sample of
subjects. Cross validation, which usually gives lower predictive
values than those obtained on the learning sets, is the recom-
mended way of evaluating the predictive accuracy of a given
marker at the individual level. Our results may thus better reﬂect
the true predictive value of structural imaging on a 24-month
period. With regards to this predictive capacity, it is important
to acknowledge, ﬁrst, that the conversion rate over 2 years in
our amnestic MCI sample was very high, reaching 59%
(72/122). Such high annual conversion rates of about 27–30%
in amnestic MCI subjects recruited within the framework of clinical
settings such as the ADNI study have been reported recently,
reaching 28% in the study by Schmidtke and Hermeneit (2008)
and 34% in the study by Rozzini et al. (2007). Such high rates
are likely to result from the way subjects are recruited and the
diagnosis criteria used for the enrolment of amnestic MCI subjects.
It is interesting to compare these rates to those derived from
population cohorts or community-based studies: the annual
conversion rate observed in the population cohort studied by
Lopez et al. (2007) was 18% for probable MCI, and the annual
rate reported in the community-based study by Fischer et al.
(2007) was 19%. Thus, the conversion rate in the ‘population’
of MCI subjects could be considered to be about 20% per year,
compared with 30% in MCI samples ‘enriched’ with patients with
early Alzheimer’s disease as recruited for clinical studies.
The inﬂuence of such a difference on the accuracy of the NTI
used to predict conversion to Alzheimer’s disease in the general
population of amnestic MCI can be evaluated by comparing the
positive and negative predictive values (PPV and NPV) of the NTI
using the Alzheimer’s disease prevalence observed at 24 months in
our ADNI amnestic MCI group (59%) and in the general amnestic
MCI population (40%) (Fischer et al., 2007; Lopez et al., 2007).
The computed positive predictive value on the ADNI sample
is 83% compared with 69% in the general amnestic MCI
population, whereas the negative predictive value increases from
71% in the ADNI population to 85% in the amnestic MCI
population. The values obtained in the general amnestic MCI pop-
ulation supports the notion that the NTI still conveys useful
information in clinical practice for the prediction of conversion
from the amnestic MCI stage to Alzheimer’s disease.
As suggested by Stern (2006), clinical evaluation alone may
prove insufﬁcient for the early diagnosis of Alzheimer’s disease.
Indeed, it suffers from the confounding effect of the cognitive
reserve and cannot directly reveal the underlying pathology.
Stern stressed the fact that it would be wise to focus on the
development of surrogate markers such as neuroimaging, which
may be less affected by the cognitive reserve. Our results strongly
support this suggestion: indeed, we showed that cognitive testing,
even when combined with education level, could not predict the
evolution to Alzheimer’s disease as accurately as the NTI. Besides,
using education as a proxy for cognitive reserve and the NTI as a
proxy for Alzheimer’s disease pathological burden, we showed
that highly educated subjects had a signiﬁcantly decreased NTI
whereas their MMSE was not affected. This result indicates that
the NTI, being less affected by the cognitive reserve than an index
of global functioning such as the MMSE, may prove more sensi-
tive for the early diagnosis of Alzheimer’s disease, in particular in
highly educated subjects. This notion is conﬁrmed by the post hoc
analyses, which revealed no differences between progressive MCI
subjects and Alzheimer’s disease patients in terms of NTI, but a
signiﬁcant difference in terms of MMSE. We also obtained further
consistent results by testing the effect of education level on the
timeline of conversion to Alzheimer’s disease: progressive MCI
subjects who converted to Alzheimer’s disease earlier than
12 months after baseline had a signiﬁcantly lower level of
education than those who converted later than 12 months after
baseline. This result supports the cognitive reserve hypothesis
within the progressive MCI group, since it indicates that
individuals with a higher degree of education have less apparent
symptoms for a longer time. Moreover, our results show that
stable MCI subjects with an NTI negative score had a high
education level, even slightly higher than that of the progressive
MCI subjects who converted to Alzheimer’s disease later than
Table 4 Contingency table of amnestic MCI subjects
misclassiﬁed by the NTI
sMCI pMCI
Educational level 15 or less 4 8
Educational level more than 15 15 6
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prevented them from showing clinical signs of dementia
24 months after baseline, while having an advanced Alzheimer’s
disease pathology. Study of the clinical status 36 months after
baseline will indicate if, as predicted by the NTI, most of these
subjects eventually converted to Alzheimer’s disease.
We therefore believe that NTI could be very useful to predict
conversion to Alzheimer’s disease, especially for subjects with
a high level of education. The cognitive reserve is particularly
confounding for these subjects because it prevents cognitive
testing from being able to efﬁciently detect their underlying
disease at an early stage. On the other hand, cognitive reserve
seems less confounding with regard to structural changes in
these subjects. Therefore, the NTI is able to detect the disease
up to 24 months before signs of overt dementia are readily
observed.
The cognitive reserve hypothesis has already been investigated
for the Alzheimer’s disease population in recent studies
(Sole-Padulles et al., 2007; Garibotto et al., 2008; Hanyu et al.,
2008; Kemppainen et al., 2008), which found that, for a given
level of cognitive burden, Alzheimer’s disease patients with a
higher education level had a lower regional cerebral blood ﬂow
(Hanyu et al., 2008), a higher Pittsburgh Compound B uptake
(Kemppainen et al., 2008), a lower glucose metabolic rate
(Garibotto et al., 2008; Kemppainen et al., 2008) and a lower
brain volume (Sole-Padulles et al., 2007) than Alzheimer’s disease
patients with lower levels of education. Sole ´ Padulle ´s et al. (2007)
extended these results to a small amnestic MCI group, while
Garibotto et al. (2008) showed that MCI converters with a
higher education level had a relatively lower glucose metabolism.
To the best of our knowledge, our study is the ﬁrst to investigate
the relation between cognitive reserve, structural changes and
the timeline of evolution to Alzheimer’s disease.
The relationships between cortical thickness and education level
might be more complex, however, than the cognitive reserve
hypothesis suggests. We observed the same effects in healthy
controls as in the amnestic MCI group, subjects with a higher
degree of education having a lower NTI. Similar results were
found by Coffey et al. (1999), who concluded that highly
educated healthy subjects managed to remain healthy while
having more age-related atrophy. Im et al. (2006) studied the
links between cortical thickness, level of education and fractal
dimension of the cortical surface for young healthy subjects, and
found that high education level was associated with a high fractal
dimension of the cortical surface, which itself was associated with
small cortical thickness. Their results may lead to the conclusion
that a high education level is associated with low cortical
thickness, even for young healthy subjects. On the other hand,
Sole ´-Padulle ´s et al. (2007) found a positive correlation between
education level and brain volume on a small population of healthy
elderly subjects. It remains unclear whether the effect of education
that we observed is related to the pathology at a preclinical phase
or whether cortical thickness is directly affected by education level.
Future work on younger populations may be required to address
this issue.
One limitation of our study comes from the high education level
of our population, and the effect of education on people with a
low education level (education level 410 years) could not really
be accounted for. This issue may need further study, including
younger healthy subjects. However, the main results of our
study were only slightly affected by this limitation since we
emphasize that studying anatomical changes may be beneﬁcial,
particularly for highly educated subjects.
Another limitation comes from the novelty of our methodolog-
ical approach. A comparative validation may be required, for
example, by comparing our results in terms of predictive value
with those of other studies on the ADNI population. However,
we have given evidence that our method is reliable, since it had
a high predictive value on the Alzheimer’s disease population, and
an encouraging predictive value on the amnestic MCI population.
Also, our results on the cognitive reserve are in accordance with
those of the current literature.
Using a new diagnostic criterion based on the NTI, we have
highlighted the fact that Alzheimer’s disease may be characterized
by structural changes that can be detected up to 24 months
before the current clinical criteria for Alzheimer’s disease are
fulﬁlled. This result supports a recent proposal (Dubois et al.,
2007) that emphasizes the need to revise the Neurological
Disorders and Stroke-Alzheimer Disease and Related Disorders
criteria in order to improve the accuracy of Alzheimer’s disease
diagnosis and to make the diagnosis at the earliest stages of
the disease. The authors propose new criteria which include
one or more biomarkers, among which is MRI structural neuro-
imaging. They however point out that there is still no MRI-
based methodology that has been completely validated as
suitable for integration in clinical routine. Our study shows
that, among subjects meeting MCI criteria, the NTI can anticipate
the diagnosis of Alzheimer’s disease 2 years before the clinical
criteria are fulﬁlled. The NTI has shown promising results at
the individual level on a large population and is an operator
independent, fully automated and quick method based on a
single 1.5T MRI scan. It can therefore be easily integrated into
clinical routine to improve the early diagnosis of Alzheimer’s
disease.
Supplementary material
Supplementary material is available at Brain online.
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